• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
Home
  • Research
  • Biotech
    • Clinical Data
    • Venture Capital
    • Deals
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending Topics
    • Cell & Gene Therapy
    • COVID-19
  • Podcasts
  • Resources
    • Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
Search Icon
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Research
  • Biotech
    • Clinical Data
    • Venture Capital
    • Deals
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending Topics
    • Cell & Gene Therapy
    • COVID-19
  • Podcasts
  • Resources
    • Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events

Presage Biosciences

MedTech

Takeda, Presage microdose cancers to see how immune cells fight

Takeda is examining two therapies that could help break down the barriers protecting solid tumors from the body's immune system.
Conor Hale Apr 13, 2022 4:34pm

Merck taps tumor-microdosing Presage for phase 0 trials

Mar 2, 2021 9:50am

Presage inks 3rd deal around phase 0 studies—with more to come

Aug 27, 2019 8:00am

Celgene taps Presage's microdosing tech for phase 0 cancer studies

May 2, 2019 8:00am

Celgene, Takeda invest in intratumoral microdosing firm Presage

Jul 17, 2018 8:00am
Home
  • Connect
    • The Team
    • Advertise
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
  • ©2022 Questex LLC All rights reserved.
  • Terms of use
  • Privacy Policy